儿童肿瘤及造血干细胞移植中抗菌预防用药指南
该指南由国际多学科专家组采用GRADE方法制定,基于114项随机试验的系统评价,针对儿童肿瘤及造血干细胞移植患者系统性抗菌预防提出推荐。推荐对强化化疗的急性髓系白血病和复发急性淋巴细胞白血病患儿进行弱推荐预防,对诱导化疗的急性淋巴细胞白血病、自体及异体移植弱推荐不常规预防,对预期不导致长期严重中性粒细胞减少者强推荐不常规预防;若使用,推荐左氧氟沙星。
要点
- 强化化疗的AML和复发ALL患儿可弱推荐系统性抗菌预防
- ALL诱导化疗、自体及异体HSCT患儿弱推荐不常规预防
- 预期不出现长期严重中性粒细胞减少者强推荐不常规预防
核心结论
- 对强化化疗的AML和复发ALL患儿弱推荐系统性抗菌预防,对ALL诱导化疗、自体及异体HSCT弱推荐不常规预防,对预期不导致长期严重中性粒细胞减少者强推荐不常规预防。
研究设计与样本
- 国际多学科专家组采用GRADE方法,基于系统评价制定的临床实践指南。
- 系统评价识别了114项符合条件的抗生素预防随机试验。
主要发现
- 系统评价共纳入114项符合条件的抗生素预防随机试验。
关键数值与推荐
- 对接受强化化疗的急性髓系白血病和复发急性淋巴细胞白血病患儿,弱推荐系统性抗菌预防。
- 对接受诱导化疗的急性淋巴细胞白血病、自体HSCT和异体HSCT患儿,弱推荐不常规使用系统性抗菌预防。
- 对治疗预期不会导致长期严重中性粒细胞减少的患儿,强推荐不常规使用系统性抗菌预防。
- 若使用预防,推荐在严重中性粒细胞减少期间使用左氧氟沙星。
临床怎么用
- 根据患儿肿瘤类型、化疗阶段和HSCT类型决定是否启动系统性抗菌预防。
- 仅在严重中性粒细胞减少期间考虑使用左氧氟沙星进行预防。
局限性
- 未来研究应评估预防的长期有效性和不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacteremia and other invasive bacterial infections are common among children with cancer receiving intensive chemotherapy and in pediatric recipients of hematopoietic stem cell transplantation (HSCT). Systemic antibacterial prophylaxis is one approach that can be used to reduce the risk of these infections. Our purpose was to develop a clinical practice guideline (CPG) for systemic antibacterial prophylaxis administration in pediatric patients with cancer and those undergoing HSCT. METHODS: An international and multidisciplinary panel was convened with representation from pediatric hematology/oncology and HSCT, pediatric infectious diseases (including antibiotic stewardship), nursing, pharmacy, a patient advocate, and a CPG methodologist. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to generate recommendations based on the results of a systematic review of the literature. RESULTS: The systematic review identified 114 eligible randomized trials of antibiotic prophylaxis. The panel made a weak recommendation for systemic antibacterial prophylaxis for children receiving intensive chemotherapy for acute myeloid leukemia and relapsed acute lymphoblastic leukemia (ALL). Weak recommendations against the routine use of systemic antibacterial prophylaxis were made for children undergoing induction chemotherapy for ALL, autologous HSCT and allogeneic HSCT. A strong recommendation against its routine use was made for children whose therapy is not expected to result in prolonged severe neutropenia. If used, prophylaxis with levofloxacin was recommended during severe neutropenia. CONCLUSIONS: We present a CPG for systemic antibacterial prophylaxis administration in pediatric cancer and HSCT patients. Future research should evaluate the long-term effectiveness and adverse effects of prophylaxis.
引用
- Lehrnbecher T, Fisher BT, Phillips B, et al. Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2020. PMID: 31676904. doi:10.1093/cid/ciz1082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。